Sagar Lonial on Muck Rack

Sagar Lonial

Atlanta
As seen in: JCO Oncology Practice, Nature, Taylor & Francis Online, Science Magazine, The Lancet, MedPage Today, Emory Report, Healio, HemOnc Today, MDEdge, MDedge Hematology and Oncology and
Professor at @EmoryUniversity, Chair of Dept. Hem & Med Onc at @EmoryMedicine, Chief Medical Officer @WinshipAtEmory. Opinions=my own. #mmsm
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sagar

Contact Sagar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mezigdomide Regimen Boosts PFS in Relapsed/Refractory Multiple Myeloma

|
By Russ Conroy, Tim Cortese, Sagar Lonial
| ONCOLOGY journal
Combining oral mezigdomide with carfilzomib (Kyprolis) and dexamethasone demonstrated a statistically significant and clinically meaningful progression-free survival (PFS) improvement vs carfilzomib/dexamethasone alone among patients with relapsed/refractory multiple myeloma, according to a press release on findings from the phase 3 portion of the SUCCESSOR-2 trial (NCT05552976).1 The safety data revealed that the profile of mezigdomide was comparable with prior reports of the agent and other...
Open in Who Shared Issue with article?

Unraveling the Potential of Iberdomide and CELMoDs in Multiple Myeloma

|
By Sagar Lonial
| ONCOLOGY journal
In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma.
Open in Who Shared Issue with article?

How do the Resources Available to Patients With Cancer Differ by Treatment Settings?

|
By Loretta J Nastoupil, Ryan Scott , Sagar Lonial
| ONCOLOGY journal
State-specific support policies and hospital-led financial navigation programs serve as essential tools for mitigating the socioeconomic burden of oncology care, according to Loretta Nastoupil, MD. In an interview with CancerNetwork®, Nastoupil detailed the divergent financial challenges facing patients in rural community settings vs those at large academic metroplexes, highlighting that "hidden" costs, such as missed work and travel, can dictate treatment feasibility.
Open in Who Shared Issue with article?
See all 112 licensed articles (224 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Sagar

Contact Sagar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified